Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018)

Crinetics Pharmaceuticals (CRNX) has 2 years of Preferred Stock Liabilities data on record, last reported at $93.0 million in Q2 2018.

  • For Q2 2018, Preferred Stock Liabilities changed N/A year-over-year to $93.0 million; the TTM value through Jun 2018 reached $93.0 million, changed N/A, while the annual FY2017 figure was $29.7 million, 67.42% up from the prior year.
  • Preferred Stock Liabilities reached $93.0 million in Q2 2018 per CRNX's latest filing, up from $29.7 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $93.0 million in Q2 2018 and bottomed at $29.7 million in Q4 2017.